Treace Medical Concepts, Inc（TMCI）のニュースとイベントTMCITreace Medical Concepts, Inc

Treace Medical Presents Results from Three Clinical Studies at AOFAS Annual Meeting

Treace Medical announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society, or AOFAS, annual meeting in Seattle, Washington. The presentations include data on the milestone five-year ALIGN3D Lapiplasty, the MTA3D Adductoplasty and the SPRINT SpeedPlate clinical studies. Featured data from the ALIGN3D Lapiplasty clinical study included final analysis of 137 of 173 total patients treated with five years of follow-up following the Lapiplasty Procedure. The data showed: early return to weight bearing in a walking boot at an average 8.4 days; low radiographic recurrence rates of 0.8% using HVA greater than 20 degrees and 5.3% using HVA greater than 15 degrees at five years; and clinically significant reduction in patient-reported scores through five years. The MTA3D Adductoplasty study featured interim data from the study of patients undergoing both the Adductoplasty and Lapiplasty procedures included interim analysis of 59 of 66 and 35 of 66 patients treated with at least one- and two-year follow-up, respectively. The data showed: early return to weight bearing in a walking boot at an average 7.6 days; clinically significant improvement and maintenance of radiographic measures of both midfoot and 3D bunion correction through 24 months and clinically significant reduction in pain and patient-reported scores through 24 months. The SPRINT SpeedPlate featured data from the one-year, multicenter study included final analysis of 89 of 91 total patients following MTP and/or TMT joint arthrodesis using SpeedPlate Rapid Compression Implants. The data showed: early return to weight bearing in a walking boot at an average nine days; high union rates with clinical and radiographic healing in 96.6% of patients at 12 months and clinically significant improvements in radiographic correction at six weeks and maintained through 12 months in patients with hallux valgus.

Company Raises 2026 Revenue Guidance to $204M-$212M

$221.8M. The company said, "The Company is raising its full-year 2026 revenue guidance to be in the range of $204 million to $212 million, representing a decline of 4% to 0% compared to full-year 2025. This compares to previous revenue guidance of $202 million to $212 million. The Company is updating its expectation of a loss in Adjusted EBITDA in the range of $3.0 million to $5.0 million for full year 2026, as compared to previous guidance of a loss in the range of $4.0 million to $6.0 million. The Company reported a loss of $3.9 million in the full-year 2025."

Treace Medical Reports Q2 Revenue of $45.38M

Reports Q2 revenue $45.38M, consensus $43.92M. "We are pleased with our second quarter results which were driven by accelerating year-over-year case volumes and market share gains resulting from increasing surgeon adoption of our comprehensive bunion portfolio as well as our expanding line of new technologies - now providing us access to a broader range of procedures throughout the foot & ankle," said John T. Treace, CEO and Chairman of Treace Medical. "We continue to focus on investing in growth initiatives to leverage our expanded portfolio, while driving profitability, positioning us for stronger growth in the second half of the year."